Cover Image
市場調查報告書

Alnylam Pharmaceuticals, Inc.:開發中產品分析

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224581
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
Alnylam Pharmaceuticals, Inc.:開發中產品分析 Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月27日 內容資訊: 英文 88 Pages
簡介

Alnylam Pharmaceuticals, Inc.是專門從事基於RNA干擾法(RNAi)的新治療藥之新創、開發、銷售的生物醫藥品企業。該公司目前正在推動「Alnylam 5x15」計劃,以透過遺傳子要素來開發針對疾病的RNAi型治療藥。

本報告提供美國的生物醫藥品企業──Alnylam Pharmaceuticals, Inc.(Alnylam)的醫藥品研究開發進展相關分析,提供該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品的簡介與開發情形,以及該公司簡介及最新趨勢等調查。

目錄

Alnylam Pharmaceuticals, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:合作產品
    • 合作產品/並用治療模式

開發中產品的概要

  • 後期階段的開發中產品
    • PhaseⅢ產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • PhaseⅡ產品/並用治療模式
    • PhaseⅠ產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • patisiran
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • ALN-TTRSC
  • asvasiran sodium
  • ALN-AT3
  • ALN-PCS02
  • ALN-PCSsc
  • ALN-TTR-01
  • ALN-VSP
  • ALN-AAT
  • ALN-ANG
  • ALN-APC
  • ALN-AS1
  • ALN-CC5
  • ALN-HPN
  • ALN-HTT
  • ALN-TMP
  • 癌症·病毒性感染疾病樹突狀細胞疫苗
  • LNP-dsP21-322-2'F
  • 帕金森氏症用RNAi治療藥
  • SIRNA-034
  • 罕見疾病用微型核糖核酸

開發平台分析

  • 標的別
  • 各投藥法
  • 分子類別
  • 各作用機制

開發中產品的最新趨勢

暫停開發的產品

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地·子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08097CDB

Summary

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
  • The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alnylam Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alnylam Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alnylam Pharmaceuticals, Inc. Snapshot
    • Alnylam Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alnylam Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alnylam Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PCSsc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-CC5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-GO1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HBV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TTRsc02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-VSP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AC3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AGT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PDL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HDV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Hepatic Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alnylam Pharmaceuticals, Inc. - Dormant Projects
  • Alnylam Pharmaceuticals, Inc. - Company Statement
  • Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alnylam Pharmaceuticals, Inc., Key Information
  • Alnylam Pharmaceuticals, Inc., Key Facts
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase III, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase II, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase I, 2016
  • Alnylam Pharmaceuticals, Inc. - Preclinical, 2016
  • Alnylam Pharmaceuticals, Inc. - Discovery, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Alnylam Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top